产品描述
PD-1/PD-L1-IN 7 is a human PD-1/PD-L1 protein/protein interaction inhibitor with an IC50 of 0.213 nM. PD-1/PD-L1-IN 7 has anticancer and antiviral functions[1].
体外活性
PD-1/PD-L1-IN 7 (compound 139) enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. PD-1/PD-L1-IN 7 also enhances the frequency of GrB+ cells among HBV-specific CD8+ and CD4+ T cells. The ability of PD-1/PD-L1-IN 7 to enhance the antiviral functions of HBV-specific CD8+ and CD4+ T cells in vitro is comparable to those of Durvalumab[1].
体内活性
PD-1/PD-L1-IN 7 (Compound 139; 10-50 mg/kg; intraperitoneal injection, daily, for 6 days) treatment shows >90% PD-L1 target occupancy (TO) on the tumor cells. PD-1/PD-L1-IN 7 significantly inhibits tumor growth in a human PD-L1 expressing MC38 mouse colorectal tumor model[1].
Cas No.
2374856-75-2
分子式
C34H36Cl2N8O4
分子量
691.61
别名
Evixapodlin
储存和溶解度
DMSO:50 mg/mL (72.30 mM),Need ultrasonic
Powder: -20°C for 3 years
In solvent: -80°C for 2 years